Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes

NCT06535789 is registered in ClinicalTrials.gov with Jaeb Center for Health Research as lead sponsor.

NCT NCT06535789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06535789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes
Lead sponsor
Jaeb Center for Health Research
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 31, 2025
Completion date
July 31, 2025
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, gestational, glucose intolerance during pregnancy, glucose metabolism disorders, pregnancy complications